Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9465382 | 0.95 | CXCR4 (0.54) | CXCR4HRH3LMNAPOLBHDAC1 | |
| SCHEMBL13509614 | 0.88 | CXCR4 (0.54) | CXCR4HRH3LMNAPOLBHDAC1 | |
| SCHEMBL13508572 | 0.87 | CXCR4 (0.53) | CXCR4HRH3LMNAPOLBHDAC1 | |
| SCHEMBL13186652 | 0.85 | CXCR4 (0.52) | CXCR4HRH3LMNAPOLBHDAC1 | |
| SCHEMBL13995495 | 0.81 | CXCR4 (0.51) | CXCR4HRH3LMNAPOLBHDAC1 | |
| SCHEMBL13090356 | 0.81 | CXCR4 (0.50) | CXCR4HRH3LMNAPOLBHDAC1 | |
| SCHEMBL12644336 | 0.80 | HRH3 (0.41) | CXCR4HRH3 | |
| SCHEMBL278629 | 0.79 | RIPK1 (0.45) | CXCR4HRH3ALDH1A1PRMT5WDR77 | |
| SCHEMBL19463939 | 0.79 | CHRNB2 (0.56) | LMNAALDH1A1 | |
| SCHEMBL14235834 | 0.79 | CHRNB2 (0.56) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017173048-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARSHAKOON NAMAL CHITHRANGA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARNER CHILCOTT COMPANY, LLC | 2010-12-02 | — | — | US | disclosed |
| US-7790748-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| US-7247648-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CXCR4 2314/4885HRH3 1610/4885LMNA 3763/4885 |
| US-20120115876-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | CXCR4 1945/4885HRH3 133/4885LMNA 2666/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | CXCR4 889/4885HRH3 1540/4885LMNA 1689/4885 |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, CD4 | CXCR4 2249/4885HRH3 166/4885LMNA 2799/4885 |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | CXCR4 1945/4885HRH3 133/4885LMNA 2666/4885 |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | OPRM1, OPRL1, OPRD1 | CXCR4 566/4885HRH3 236/4885LMNA 2470/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CXCR4 607/4885HRH3 976/4885LMNA 2799/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | CXCR4 3399/4885HRH3 3185/4885LMNA 3330/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | CXCR4 958/4885HRH3 1459/4885LMNA 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.